This feasibility study did not include pharmacokinetic/pharmacodynamic analyses—specifically LC–MS/MS quantification of SN-38, CPT-11, and APC in tumor versus plasma/major organs; assessments of CE2 expression and enzymatic activity in tumor and non-tumor tissues; and biodistribution/persistence of hTERT-ADSC.CE2 after systemic delivery. The gene discussed is APC; the disease is neoplasm.